If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSymphony Env. Regulatory News (SYM)

Share Price Information for Symphony Env. (SYM)

Share Price is delayed by 15 minutes
Get Live Data
8.25    0.00 (0.00%)
Bid:
7.50
Ask:
9.00
Spread: 1.50 (20.00%)
Market Cap: £19.50m
SYM Live PriceLast checked at - London Stock Exchange

Intraday Symphony Env. Share Chart

New expanded FDA approval for d2p food packaging

14 Jul 2021 07:00

RNS Number : 1455F
Symphony Environmental Tech. PLC
14 July 2021
 

 

 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

 

 

14 July 2021

 

SYMPHONY ENVIRONMENTAL TECHNOLOGIES PLC

 

("Symphony", "Company" or the "Group")

New enhanced and expanded FDA approval for Symphony's antimicrobial food packaging

Symphony Environmental Technologies Plc (AIM:SYM), global specialists in technologies that make plastic and rubber products "smarter, safer and sustainable" is delighted to announce that it has received approval from the U.S. Food & Drug Administration ("FDA") for its d2p antimicrobial food contact technology, for a much greater loading of the d2p technology, and also wider use, of Symphony's original bread-packaging approval under FCN no. 2031, as announced on 26 February 2020 (RNS number: 1106E).

More specifically, the FDA's approval for Symphony's d2p antimicrobial food contact technology, now applies to all types of polyolefin and polyester film for wrapping bread, instead of just linear low density polythene ("LLDPE"). Low density polythene ("LDPE") and polypropylene ("PP") are common packaging materials which are both now included. Symphony's d2p technology is intended to inhibit the growth of bacteria on the surface of the packaging film and is vital to a very hygiene-conscious industry.

This important wider approval, given under FCN no. 2139 without limit of time, also allows up to three times increased loading of d2p technology in what is an innovative treatment to multi-layer plastic films most commonly used in bread-packaging, giving greater flexibility, efficacy and ultimately, greater value for Symphony's customers and Symphony itself. The Board therefore anticipate an acceleration of the commercial process in the near term.

By virtue of the Federal Food Drug and Cosmetic Act (21 USC 348(h)(2)(C)) this approval is effective only for Symphony and does not include any similar or identical substance manufactured or prepared by a company or person other than Symphony.

According to the Global Data report 2019 (Bread & Rolls (Bakery & Cereals) Market in the United States of America - Outlook to 2023) the US Packaging/Industrial Bread & Rolls Market by Volume in 2018 was 3,628 million kgs with a market value of more than $20 billion. This represents a significant opportunity for Symphony as it expects the d2p solution to prove a key source of commercial differentiation for packaged bread manufacturers.

Pre-commercial trials for the USA and a number of other countries had already been progressing well in anticipation of today's widened approval, with trial data showing significant benefits from these further enhanced, and now FDA-approved, d2p treated films.

Michael Laurier, CEO of Symphony, said "This innovative multi-layer film treatment with d2p has been developed through our customer-focused trials following last year's FDA approval. The benefits for our customers were already significant and so we are delighted to have obtained this more enhanced approval for our d2p bread applications in the USA. 

Symphony already generates significant revenues from the baking industry from our d2w biodegradable technology in plastic packaging, and we are seeing considerable interest in our FDA-approved, d2p antimicrobial technology for bread packaging. d2p is synergistic with d2w biodegradable technology and is expected to be sold to many of our current customers as well as new ones separately, or as a combined treatment.

The value proposition is now so much greater with better efficacy and more flexibility. We are confident of announcing the start of commercial sales during this year and in the medium term, generating significant revenues from d2p treated films, not just in the USA, but in other key regions of the world."

 

Enquiries

Symphony Environmental Technologies Plc

 

Michael Laurier, CEO

Tel: +44 (0) 20 8207 5900

Ian Bristow, CFO

 

www.symphonyenvironmental.com

 

 

 

Zeus Capital Limited (Nominated Adviser and Joint Broker)

 

David Foreman / Nick Cowles / Kieran Russell (Corporate Finance)

Tel: +44 (0) 161 831 1512

Dominic King / Victoria Ayton (Sales)

Tel: +44 (0) 203 829 5000

 

 

Hybridan LLP (Joint Broker)

Claire Louise Noyce

 

 

Tel: +44 (0) 203 764 2341

The person responsible for arranging the release of this information is Michael Laurier, CEO of the Company.

 

NOTES TO EDITORS:

 

About Symphony Environmental Technologies plc 

 

https://www.symphonyenvironmental.com

Symphony has developed a range of additives, concentrates and master-batches marketed under its d2p® ("designed to protect") trademark, which can be incorporated in a wide variety of plastic and non-plastic products so as to give them protection against many different types of bacteria, viruses, fungi, algae, moulds, and insects, and against fire. d2p products also include odour, moisture and ethylene adsorbers as well as other types of food-preserving technologies. Symphony has also launched d2p anti-microbial household gloves and toothbrushes (most recently in Bahrain), and is developing a range of other d2p finished products for retail sale.

 

Symphony has developed and continues to develop, a biodegradable plastic technology which helps tackle the problem of microplastics by turning ordinary plastic at the end of its service-life into biodegradable materials. It is then no longer a plastic and can be bioassimilated in the open environment in a similar way to a leaf. The technology is branded d2w® and appears as a droplet logo on many thousands of tonnes of plastic packaging and other plastic products around the world. In some countries, most recently Saudi Arabia, oxo-biodegradable plastic is mandatory.

 

The Group has complemented its d2w biodegradable product range with d2c "compostable resins and products" that have been tested to US and EU composting standards.

 

Symphony has also developed the d2Detector®, a portable device which analyses plastics and detects counterfeit products. This is useful to government officials tasked with enforcing legislation, and Symphony's d2t tagging and tracer technology is available for further security.

 

Symphony has a diverse and growing customer-base and has established itself as an international business with 74 distributors around the world. Products made with Symphony's plastic technologies are now available in nearly 100 countries and in many different product applications. Symphony itself is accredited to ISO9001 and ISO14001.

 

Symphony is a member of The OPA (www.biodeg.org) and actively participates in the Committee work of the British Standards Institute (BSI), the American Standards Organisation (ASTM), the European Standards Organisation (CEN), and the International Standards Organisation (ISO).

 

Further information on the Group can be found at www.symphonyenvironmental.com and twitter @SymphonyEnv See also Symphony on Instagram. A Symphony App is available for downloading to smartphones.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGPUGWMUPGPPW
Date   Source Headline
30th Jun 20261:34 pmRNSAudited Final Results
24th Jun 20267:00 amRNS-RContinued Inclusion in the LSE Green Economy Mark
23rd Jun 20267:00 amRNSPreliminary Results
22nd Jun 202612:15 pmRNSExtension of Convertible Loan Agreements
22nd Jun 20267:00 amRNS-RSaudi Plastics & Petrochem,Print & Pack Exhibition
15th Jun 20269:13 amRNSIndia Market Update
12th Jun 20269:00 amRNS-RAppointment of Distributor in North Africa
28th Apr 20267:00 amRNSPre-Close Trading Update
7th Apr 20267:00 amRNS-RHSAC report
23rd Mar 20267:00 amRNSDirector/PDMR dealing - Bed & ISA
18th Feb 20268:28 amRNSNew consultancy agreement and grant of options
12th Jan 20267:00 amRNS-Rd2w Biodegradable Plastic Technology
22nd Dec 20257:00 amRNSCanadian govt policy shift re. single use plastics
22nd Dec 20257:00 amRNSCanadian govt policy shift re. single use plastics
22nd Dec 20257:00 amRNSHolding(s) in Company
22nd Dec 20257:00 amRNSHolding(s) in Company
18th Dec 20252:16 pmRNSStrategic MoU Signed with Arsan Global
18th Dec 20252:16 pmRNSStrategic MoU Signed with Arsan Global
17th Dec 20253:33 pmRNSTrading and Middle East operations update
28th Nov 20257:00 amRNS-RAlignment with BB-REG-NET's Recommendations
26th Nov 202510:25 amRNSExtension to Convertible Loan Agreements
10th Nov 20257:00 amRNS-RNew product launch, South Korea
29th Oct 20257:00 amRNS-RRoyal Society Study on Ocean Biodegradable Plastic
24th Oct 20257:00 amRNS-RCEO speaks at Argus Fertiliser Conference
16th Oct 20257:00 amRNS-RSuccessful attendance at the K-Show
30th Sep 20257:00 amRNSInterim Results for 6 Months Ended 30 June 2025
26th Sep 20257:00 amRNS-RCEO Speaks at US SPE Conference
19th Sep 20254:55 pmRNSEPA Ireland update
23rd Jul 20251:53 pmRNSResult of AGM
23rd Jul 20257:00 amRNSAGM Statement
8th Jul 202510:25 amRNSUpdate on Approval from the Republic of Ireland
25th Jun 20251:49 pmRNSHolding(s) in Company
23rd Jun 202512:37 pmRNSApproval of d2w products in Ireland
18th Jun 20257:00 amRNSPosting of Annual Report and Notice of AGM
12th Jun 20257:00 amRNSPreliminary Results
11th Jun 202510:15 amRNSChange of Subscription Amount
5th Jun 20257:00 amRNSChange of Equity Subscriber
14th May 202511:50 amRNSHolding(s) in Company
8th May 202510:35 amRNSEquity Subscription
10th Apr 20259:00 amRNSExtended Scientific Study on Microplastics in Soil
9th Apr 202510:00 amRNSTransfer of Shareholding and Assignment of CLAs
11th Mar 20257:00 amRNS-RStudy Findings - No Trace of Microplastics
10th Mar 20252:21 pmRNSHolding(s) in Company
3rd Mar 20257:00 amRNS-RRuling on Biodegradable Plastic Legislation
23rd Dec 202412:39 pmRNSOption amendments & grant of options
1st Nov 202411:15 amRNSGrant of Options
9th Sep 20247:00 amRNSInterim Results for 6 Months Ended 30 June 2024
23rd Aug 20247:00 amRNSNotice of Results and Investor Presentation
28th Jun 202412:49 pmRNSResult of AGM
28th Jun 20247:00 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.